<- Previous Next -> Message 2232 of 2234 Reply
Immune Response AIDS Therapy Boosts Immune Cells in Early RUSH__2000
Jul 2 1998
7:53AM EDT
Geneva, July 2 (Bloomberg) - Immune Response Corp.'s AIDS therapy, Remune, developed in part by the late Jonas Salk, appears to help reduce the amount of HIV in the blood, early research shows.
Preliminary results of a 43-patient study were presented at the 12th World AIDS Conference in Geneva. Remune is intended to stimulate the immune system to attack HIV.
In 18 of 21 patients, or 86 percent, the amount of HIV in the blood dropped to fewer than 40 copies a milliliter. In the group that received only AZT, 3TC and Crixivan, 12 out of 18, or 16 percent, had the same success in treatment.
At the start of the test, the median count of HIV in the blood was 8,159 copies. ''Although it's preliminary, it's promising,'' said Elise Wang, an analyst with PaineWebber Inc., after a presentation on the study in Geneva this morning.
Wang has a ''buy'' rating on Agouron Pharmaceuticals Inc., which is working with Immune Response on the drug. Agouron, maker of the AIDS drug, Viracept, could give Immune Response as much as $77 million in a pact for the development and marketing of Remune.
Remune is in late-stage testing. If these results are these studies are positive, Immune Response could apply to the U.S. Food and Drug Administration for approval of the drug in mid 1999, the company said.
Immune Response fell 1 1/4 yesterday to 13 3/4.
IMNR: Quote | Profile | Research This Is a Reply to: Msg 2230 by betthepharm
View Replies to this Message
|
